Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
PR Newswire•06/10/2026•07:00 ET
0
Key Highlights
- ➤Compugen (CGEN) management to join H.C. Wainwright AI drug discovery fireside chat October 8
- ➤Fireside chat scheduled for 9:30 AM ET with webcast and replay available
- ➤COM701 evaluated in blinded randomized MAIA-ovarian trial for relapsed platinum-sensitive ovarian cancer
- ➤AstraZeneca evaluates licensed rilvegostomig across Phase 3, Phase 2 and Phase 1 trials
- ➤Gilead-licensed GS-0321 is being evaluated in a Compugen-conducted Phase 1 trial
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference PR Newswire
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3(rd) Annual AI Based Drug Discovery & Development Conference, being held virtually on October 8-9, 2026.
Get started
Create a free account to read the full story.